Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACKR3 | P25106 | 5/20 | 0.58 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.58 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.58 |
| ▸ | MEN1 | O00255 | 1/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.55 |
| ▸ | APP | P05067 | 3/20 | 0.54 |
| ▸ | MCHR1 | Q99705 | 2/20 | 0.52 |
| ▸ | NPC1 | O15118 | 2/20 | 0.51 |
| ▸ | RAB9A | P51151 | 2/20 | 0.51 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | USP7 | Q93009 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6498560 | 0.94 | MEN1 (0.62) | ACKR3SIGMAR1TMEM97MEN1KMT2A | |
| SCHEMBL6503460 | 0.91 | SIGMAR1 (0.52) | ACKR3SIGMAR1TMEM97APP | |
| SCHEMBL6505559 | 0.87 | EPHX2 (0.56) | ACKR3KMT2AAPPRAB9ATSHR | |
| SCHEMBL6503729 | 0.81 | EPHX2 (0.58) | MEN1KMT2AMCHR1RAB9ATSHR | |
| SCHEMBL6506029 | 0.81 | LMNA (0.55) | APPTSHRHSD17B10 | |
| SCHEMBL6501980 | 0.81 | GAA (0.69) | ACKR3APPTSHRHSD17B10POLB | |
| SCHEMBL6497288 | 0.81 | TSHR (0.53) | ACKR3MEN1KMT2AAPPTSHR | |
| SCHEMBL6507792 | 0.79 | MTNR1A (0.51) | SIGMAR1MEN1KMT2AAPPTSHR | |
| SCHEMBL6499418 | 0.79 | APP (0.46) | ACKR3APPRAB9A | |
| SCHEMBL6497700 | 0.78 | KMT2A (0.50) | MEN1KMT2AAPPTSHRHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050143372-A1 | Compounds, pharmaceutical compositions and methods of use therefor | MILLENNIUM PHARMACEUTICALS, INC. | 2005-06-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050143372-A1 | Compounds, pharmaceutical compositions and methods of use therefor | CCR8, CCL11, CCR5 | ACKR3 17/4885SIGMAR1 525/4885TMEM97 1169/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.